1,194
Views
18
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension

&
Pages 74-77 | Received 03 Dec 2008, Published online: 08 Jul 2009

References

  • Turnbull F. Effects of different blood‐pressure‐lowering regimens on major cardiovascular events: Results of prospectively‐designed overviews of randomised trials. Lancet 2003; 362: 1527–1535
  • Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252
  • Chapman N, Chang CL, Dahlof B, Sever PS, Wedel H, Poulter NR. Effect of doxazosin gastrointestinal therapeutic system as third‐line antihypertensive therapy on blood pressure and lipids in the Anglo‐Scandinavian Cardiac Outcomes Trial. Circulation 2008; 118: 42–48
  • Ohta Y, Tsuchihashi T, Onaka U, Eto K, Ueno M. Usefulness of the alpha1‐blocker doxazosin as a third‐line antihypertensive drug. Hypertens Res 2007; 30: 301–306
  • ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid‐lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967–1975
  • Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: 510–526
  • Black HR, Sollins JS, Garofalo JL. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo‐controlled study. Am J Hypertens 2000; 13: 468–474
  • Pessina AC, Ciccariello L, Perrone F, Stoico V, Gussoni G, Scotti A, et al. Clinical efficacy and tolerability of alpha‐blocker doxazosin as add‐on therapy in patients with hypertension and impaired glucose metabolism. Nutr Metab Cardiovasc Dis 2006; 16: 137–147
  • Guzik P, Wykretowicz A, Krauze T, Piskorski J, Adamska K, Milewska A, et al. Add‐on therapy with a nighttime dose of doxazosin in patients with uncontrolled hypertension: effects on autonomic modulation of the cardiovascular system. Hypertens Res 2008; 31: 443–453

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.